Sandra and Edward Meyer Cancer Center

Treating patients with advanced, metastatic esophageal cancer with an immune-system boosting drug called pembrolizumab, known by its brand name Keytruda, led to regression of tumors in some patients, according to results of a phase 2 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

New studies from Weill Cornell Medicine researchers have revealed the importance of two gene-regulation proteins in the development of common immune cell cancers called lymphomas.

Researchers at Weill Cornell Medicine, in collaboration with investigators at Dana-Farber Cancer Institute, have been awarded a three-year, $1 million grant from the U.S. Department of Defense (DoD) for prostate cancer clinical trials.

Seven Weill Cornell Medicine faculty members leading multi-institutional research teams were awarded grants from The Starr Foundation's 12th Starr Cancer Consortium Grant Competition to fund their innovative cancer research projects.

Postmenopausal women with higher levels of body fat have a significantly increased risk of developing breast cancer even if they have a normal body mass index (BMI), according to a new study.

A study of the dual pathways that process the essential vitamin folate by Weill Cornell Medicine investigators unexpectedly revealed a new way the cancer drug methotrexate works and may suggest strategies to boost its cancer-killing effects.

Dr. Massimo Loda Appointed Chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and Pathologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center

Weill Cornell Medicine investigators Dr. David Lyden and Dr. Ari Melnick have been awarded Outstanding Investigator Awards from the National Cancer Institute.

Ovarian tumors disable the immune system’s killer T cells—which protect the body by destroying infected or malignant cells—enabling the disease to flourish unchecked, according to a new study by Weill Cornell Medicine scientists.

Dr. Dan Landau has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.

A very low carbohydrate, high-fat diet called the ketogenic diet may improve the effectiveness of an emerging class of cancer drugs, according to a study in mice by investigators at Weill Cornell Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian.

A new cellular messenger discovered by Weill Cornell Medicine scientists may help reveal how cancer cells co-opt the body’s intercellular delivery service to spread to new locations in the body.

Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center researchers.

Many successful researchers cite the influence of a mentor who inspired and advised them—and that’s especially true for Dr. Kevin O’Rourke, PhD ’17.

Ongoing monitoring for genetic changes in chronic lymphocytic leukemia (CLL) during targeted treatment may allow clinicians to adjust patients’ treatments as the cancer evolves, according to a study in Nature Communications led by Weill Cornell Medicine and New York Genome Center scientists.

When Dr. Onyinye Balogun was a young girl, her father’s only sister was diagnosed with breast cancer back home in their native Nigeria. Dr. Balogun had recently immigrated to the United States with her parents, but on a return visit the severity of her aunt’s disease became clear.

Internationally renowned neuro-oncologist Dr. Howard A. Fine of Weill Cornell Medicine and NewYork-Presbyterian will receive a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer research.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer. 

Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators.

Growing up in Knoxville, Tennessee, Neel Madhukar always assumed he would become a physician.